Cancer treatment is changing. In addition to surgery, chemotherapy, radiation, and immunotherapy, integrative oncology is exploring how repurposed medications may help support cancer care. These approaches aim to work alongsidestandard treatment to improve outcomes, support the immune system, and address the complex biology of cancer.
This article explains what repurposed drugs are, how they may work, what research shows so far, and how they may be thoughtfully incorporated into a personalized integrative oncology plan.
What Are Repurposed Drugs?
Repurposed drugs are medications originally developed for other conditions but later found to have potential anticancer effects. Nutraceuticals are natural compounds or supplements that may influence cancer-related pathways.
Unlike many conventional cancer drugs that target a single biological pathway, repurposed therapies often work through multiple mechanisms at once. In integrative oncology, this is important because cancer is a complex disease involving many interacting systems.
These therapies may:
- Act directly on cancer cells by encouraging apoptosis (programmed cell death)
- Alter the tumor microenvironment to support immune function
- Reduce angiogenesis (new blood vessel formation that feeds tumors)
- Limit metastasis and affect cancer stem cells
Because they target multiple pathways, integrative oncologists often use combinations rather than relying on a single intervention.
Why Are These Therapies Receiving Attention?
Many repurposed drugs and nutraceuticals have long safety histories, are widely available, and are relatively affordable compared with newer cancer drugs. Research suggests that compounds associated with cancer prevention may also help slow cancer growth or spread when used therapeutically.
Large-scale randomized trials are limited, partly because many of these treatments are inexpensive and not patent-protected, resulting in less commercial funding for research. As a result, much of the current evidence comes from laboratory studies, animal research, observational data, and smaller clinical studies. While this evidence is not definitive, it has encouraged ongoing investigation and carefully monitored clinical use in integrative settings.
How Do Repurposed Therapies Work?
Cancer cells depend on altered metabolism, immune evasion, and abnormal signaling pathways. Many repurposed therapies appear to target several of these processes simultaneously. Research suggests they may influence cellular growth signals, inflammatory pathways, immune cell activity, and the tumor microenvironment.
Because cancer adapts easily, integrative oncologists often emphasize combination strategies. Different compounds may work together synergistically, potentially enhancing the effects of each other and of standard therapies.
Real-World Research: The METRICS Study
One example is the METRICS study, an open-label real-world trial evaluating a combination of metabolically targeted repurposed drugs—such as metformin, atorvastatin, mebendazole, and doxycycline—in patients with glioblastoma and other tumors. Early observational results suggested improved disease-free survival compared with historical controls.
These findings are encouraging, but larger clinical studies are needed to confirm results and determine which patients may benefit most.
Spotlight: Ivermectin in Oncology
As interest grows in repurposed medications for cancer care, one drug that has received increasing scientific attention is ivermectin. While originally developed as an antiparasitic medicine, researchers are exploring whether it may also play a supportive role in integrative oncology care.
This summary explains what ivermectin is, what research has shown so far, and what patients should understand when considering this therapy within an evidence-informed, medically supervised treatment plan.
Ivermectin is a macrocyclic lactone originally developed to treat parasitic infections. It has been used safely in humans for decades and has a well-established pharmacological profile. Its discovery was recognized with the 2015 Nobel Prize in Physiology or Medicine.
Why Is Ivermectin Being Studied in Cancer?
Researchers are not investigating ivermectin because cancer is parasitic — it is not. Instead, interest stems from laboratory findings showing that ivermectin interacts with cell signaling pathways that are also active in cancer biology.
Cancer cells rely on abnormal survival signals, altered metabolism, and immune evasion. Preclinical studies suggest ivermectin may influence several of these mechanisms simultaneously.
Mechanisms Under Investigation
Laboratory research indicates ivermectin may:
- Promote apoptosis (programmed cell death)
- Trigger autophagy (removal of damaged cellular components)
- Inhibit Akt/mTOR signaling (a growth and survival pathway)
- Influence Wnt/β-catenin signaling (involved in cancer stem cells)
- Reduce cancer cell proliferation
- Affect tumor-associated macrophages and immune signaling
- Potentially impair cancer cell migration and metastasis
Some studies also suggest ivermectin may sensitize tumor cells to chemotherapy in certain models.
Cancers Studied in Preclinical Models
Activity has been observed in laboratory models of:
- Breast cancer (including triple-negative)
- Colorectal cancer
- Lung cancer
- Ovarian and endometrial cancers
- Melanoma
- Leukemia and lymphoma
- Glioblastoma
It is important to emphasize that cell culture results do not automatically translate into clinical effectiveness in patients.
Human Evidence and Limitations
At present:
- No large randomized oncology trials confirm benefit.
- Published human data consist mainly of small case reports or anecdotal experiences.
- Optimal dosing for cancer has not been established.
- Pharmacokinetic considerations (blood concentration levels required for anticancer effects) remain under investigation.
In many lab studies, the concentration required to inhibit cancer cells are higher than standard antiparasitic dosing achieves in humans. This is a key scientific consideration when interpreting results.
Safety Considerations
Ivermectin has a strong safety record at approved doses. However:
- Cancer dosing strategies are not standardized.
- Drug–drug interactions (especially with chemotherapy) must be evaluated.
- Liver metabolism pathways must be considered.
- Self-prescribing is unsafe and strongly discouraged.
In integrative oncology, ivermectin — when considered — is approached cautiously, individualized, and carefully monitored.
Mebendazole in Oncology
Mebendazole is a benzimidazole antiparasitic drug used in humans. Among repurposed antiparasitics, it has the most clinical investigation in oncology.
Mechanism of Action Relevant to Cancer
Mebendazole binds to β-tubulin and disrupts microtubule formation, which is essential for cell division. This mechanism is conceptually similar to certain chemotherapy drugs that target the mitotic spindle.
Additional proposed effects include:
- Inhibition of angiogenesis
- Disruption of glucose uptake in cancer cells
- Targeting of cancer stem cells
- Downregulation of oncogenic signaling pathways
- Induction of apoptosis
- Modulation of immune signaling
Blood–Brain Barrier Penetration
One unique feature of mebendazole is its ability to cross the blood–brain barrier. This has led to interest in glioblastoma and other brain tumors.
Some small clinical efforts and observational reports have explored mebendazole as an adjunct in glioma treatment protocols, though data remain preliminary.
Human Evidence
Compared to ivermectin and fenbendazole, mebendazole has:
- Limited early-phase human data
- Case reports suggesting tolerability in oncology settings
- Inclusion in some metabolic combination protocols
However, definitive randomized data are lacking.
Safety Profile
Mebendazole is generally well tolerated at antiparasitic doses. At higher or prolonged dosing:
- Liver enzymes may elevate
- Gastrointestinal upset may occur
- Blood count monitoring may be necessary
Careful laboratory monitoring is essential when used off label in oncology.
Fenbendazole: A Critical Discussion
Fenbendazole is also a benzimidazole drug, but it is approved only for veterinary use.
It gained public attention through anecdotal online reports, including references to the book How to Starve Cancer and the widely circulated story of Joe Tippens.
Important Context About Joe Tippens Story
Joe Tippens reported remission from advanced lung cancer while taking fenbendazole. However, he was also enrolled in a clinical trial using Keytruda, an FDA-approved PD-1 inhibitor known to produce durable responses in some patients.
Checkpoint inhibitors can produce dramatic responses in patients with:
- High tumor mutational burden
- Microsatellite instability
- PD-L1 expression
Attributing remission solely to fenbendazole is scientifically problematic without controlled data.
Preclinical Evidence
Like mebendazole, fenbendazole disrupts microtubule formation. In petri dish studies, it demonstrates:
- Cancer cell growth inhibition
- Apoptosis induction
- Disruption of glucose metabolism
However, several concerns exist.
Major Concerns
- No Human Clinical Trials
There are no oncology trials establishing safety or efficacy in humans. - Absorption and Bioavailability
Fenbendazole has poor oral solubility. Achieving therapeutic blood levels may not be feasible without pharmaceutical reformulation. - Reports of Liver Injury
Case reports describe severe liver toxicity that resolved after discontinuation. - Inflammation and Possible Disease Acceleration
Some clinicians report cases of accelerated tumor progression or inflammatory spikes. - Unregulated Dosing
Online forums suggest doses ranging from 200 mg to 2,000 mg daily — without medical oversight. - Animal Studies Show Limited Benefit Alone
Preclinical studies suggest minimal effect when used as monotherapy.
When Might It Be Considered?
In advanced-stage cancers with limited treatment options, some patients pursue investigational protocols. However, this must be done:
- Under physician supervision
- With laboratory monitoring
- With full understanding of unknown risks
For early-stage or potentially curable cancers, unsupervised use poses significant risk.
Comparing the Three Agents
| Feature | Ivermectin | Mebendazole | Fenbendazole |
| Approved for humans | Yes | Yes | No (veterinary only) |
| Human oncology data | Very limited | Limited but more than others | None |
| Blood–brain barrier penetration | Limited | Yes | Unclear |
| Safety record in humans | Established at approved doses | Established at approved doses | Not approved |
| Major concern | Lack of dosing data | Need for larger trials | Liver toxicity, lack of trials |
The Takeaway for Patients
- Ivermectin and mebendazole have laboratory evidence suggesting anticancer mechanisms, but human data remain limited.
- Mebendazole has more clinical exploration than ivermectin or fenbendazole.
- Fenbendazole lacks human safety data and carries documented risks.
- Internet testimonials do not equal clinical evidence.
- Any repurposed therapy should be supervised by an oncology-trained physician.
Cancer care is complex. A disciplined, evidence-informed approach is essential to ensure that supportive strategies enhance — rather than compromise — your treatment outcomes.
Schedule a Consultation
At CAREVIVOR, we provide an oncologist-directed, holistic wellness program crafted exclusively for cancer survivors. Our approach harmonizes the precision of conventional oncology with evidence-informed integrative strategies, empowering patients to move beyond survivorship toward renewed vitality, resilience, and long-term wellness.
Dr. Young Lee, a board-certified Medical Oncologist, brings expertise in precision cancer therapy as part of our tailored supportive care offerings.
Call 410-740-7444 to schedule your personalized consultation.
REFERENCES:
- Cancer Care: Repurposed Drugs & Metabolic Interventions in Treating Cancer. Paul E. Marik, MD, FCCM, FCCP. https://imahealth.org/research/cancer-care/
- https://cancerchoices.org/